Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

被引：19

作者：

Chiappella, Annalisa ^{[1
]}

Dodero, Anna ^{[1
]}

Evangelista, Andrea ^{[2
]}

Re, Alessandro ^{[3
]}

Orsucci, Lorella ^{[4
]}

Usai, Sara Veronica ^{[5
]}

Castellino, Claudia ^{[6
]}

Stefoni, Vittorio ^{[7
]}

Pinto, Antonio ^{[8
]}

Zanni, Manuela ^{[9
]}

Ciancia, Rosanna ^{[10
]}

Ghiggi, Chiara ^{[11
]}

Rossi, Francesca Gaia ^{[12
]}

Arcari, Annalisa ^{[13
]}

Ilariucci, Fiorella ^{[14
]}

Zilioli, Vittorio Ruggero ^{[15
]}

Flenghi, Leonardo ^{[16
]}

Celli, Melania ^{[17
]}

Volpetti, Stefano ^{[18
]}

Benedetti, Fabio ^{[19
]}

Ballerini, Filippo ^{[20
]}

Musuraca, Gerardo ^{[21
]}

Bruna, Riccardo ^{[22
]}

Patti, Caterina ^{[23
]}

Leonardi, Francesco ^{[24
]}

Arcaini, Luca ^{[25
,26
]}

Magagnoli, Massimo ^{[27
]}

Cavallo, Federica ^{[28
]}

Bermema, Anisa ^{[1
]}

Tucci, Alessandra ^{[3
]}

Boccomini, Carola ^{[4
]}

Ciccone, Giovannino ^{[2
]}

Carniti, Cristiana ^{[29
]}

Pileri, Stefano Aldo ^{[30
]}

Corradini, Paolo ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy

[2] Azienda Osped & Univ Citta Salute & Sci & CPO Pie, Unit Clin Epidemiol, Turin, Italy

[3] ASST Spedali Civili Brescia, Hematol Div, Brescia, Italy

[4] Azienda Osped & Univ Citta Salute & Sci, Div Hematol, Turin, Italy

[5] Osped Oncol Armando Businco, Hematol Unit, Cagliari, Italy

[6] Azienda Osped S Croce & Carle, Div Hematol, Cuneo, Italy

[7] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[8] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Hematol Oncol & Stem Cell Transplantat Unit, Naples, Italy

[9] Azienda Osped Santi Antonio & Biagio & Cesare Arr, Div Hematol, Alessandria, Italy

[10] Ctr Riferimento Oncol Aviano CRO IRCCS, Hematol, Aviano, Italy

[11] IRCCS Osped Policlin San Martino, Unit Hematol & Cellular therapies, Genoa, Italy

[12] Fdn IRCCS Ca Granda, Div Hematol, OM Policlin, Milan, Italy

[13] Osped Guglielmo Saliceto, Hematol Unit, Piacenza, Italy

[14] IRCCS Reggio Emilia, Hematol, Azienda USL, Reggio Emilia, Italy

[15] ASST Grande Osped Metropolitano Niguarda, Div Hematol, Milan, Italy

[16] Azienda Osped Perugia, Hematol, Perugia, Italy

[17] Osped Infermi, Hematol, Rimini, Italy

[18] ASUFC, Presidio Osped Univ Santa Maria della Misericordi, Clin Hematol, Udine, Italy

[19] Azienda Osped Univ Verona, Hematol & Stem Cell Transplantat, Verona, Italy

[20] IRCCS Osped Policlin San Martino, Hematol, Genoa, Italy

[21] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Hematol unit, Meldola, Italy

[22] Osped Maggiore La Carita, Div Hematol, Novara, Italy

[23] Azienda Villa Sofia Cervello, Div Onco Hematol, Palermo, Italy

[24] Azienda Osped Univ Parma, Hematol & CTMO, Parma, Italy

[25] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Mol Med, Pavia, Italy

[26] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy

[27] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Dept Oncol & Hematol, Rozzano, Italy

[28] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Div Hematol, Azienda Osped & Univ Citta Salute & Sci, Turin, Italy

[29] Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Lab Hematol, Milan, Italy

[30] European Inst Oncol IRCCS, Div Haematopathol, Milan, Italy

来源：

LEUKEMIA | 2023年 / 37卷 / 02期

关键词：

LONG-TERM REMISSIONS; ALLOGENEIC TRANSPLANTATION; IMPACT;

D O I：

10.1038/s41375-022-01780-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; in first line, Romidepsin was added with CHOP. We designed a study combining romidepsin and CHOEP as induction before HDT + auto-SCT in untreated PTCLs (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18-65 years. A phase Ib/II trial was conducted to define the maximum tolerated dose (MTD) of Ro-CHOEP, and to assess efficacy and safety of 6 Ro-CHOEP as induction before HDT. The study hypothesis was to achieve a 18-month PFS of 70%. Twenty-one patients were enrolled into phase Ib; 7 dose-limiting toxicities were observed, that led to define the MTD at 14 mg/ms. Eighty-six patients were included in the phase II. At a median follow-up of 28 months, the 18-month PFS was 46.2% (95%CI:35.0-56.7), and the 18-month overall survival was 73.1% (95%CI:61.6-81.7). The overall response after induction was 71%, with 62% CRs. No unexpected toxicities were reported. The primary endpoint was not met; therefore, the enrollment was stopped at a planned interim analysis. The addition of romidepsin to CHOEP did not improve the PFS of untreated PTCL patients.

引用

页码：433 / 440

页数：8

共 50 条

[31] High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)
d'Amore, Francesco
Relander, Thomas
Lauritzsen, Grete F.
Jantunen, Esa
Hagberg, Hans
Anderson, Harald
Holte, Harald Jr.
Osterborg, Anders
Merup, Mats
Brown, Peter de Nully
Kuittinen, Outi
Erlanson, Martin
Ostenstad, Bjorn
Fagerli, Unn-Merete
Gadeberg, Ole
Sundstrom, Christer
Delabie, Jan
Rafkiaer, Elisabeth
Vornanen, Martine
Toldbod, Helle
BLOOD, 2011, 118 (21) : 155 - 156
[32] Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma
Eric D. Jacobsen
Haesook T. Kim
Erin Jeter
Caron Jacobson
David C. Fisher
Philippe Armand
Bone Marrow Transplantation, 2022, 57 : 1719 - 1720
[33] Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma
Jacobsen, Eric D.
Kim, Haesook T.
Jeter, Erin
Jacobson, Caron
Fisher, David C.
Armand, Philippe
BONE MARROW TRANSPLANTATION, 2022, 57 (11) : 1719 - 1720
[34] Comparison of outcome of diffuse large B-cell lymphoma versus peripheral T-cell lymphoma with high-dose chemotherapy and autologous stem cell transplantation
Angelopoulou, MK
Nademanee, A
Dagis, A
Molina, A
Fung, H
Parker, PM
O'Donnell, MR
Stein, A
Falk, P
Krishnan, A
Kogut, N
Rodriguez, R
Sahebi, F
Smith, EP
Snyder, D
Spielberger, R
Zain, J
Popplewell, L
Smith, D
Forman, SJ
BONE MARROW TRANSPLANTATION, 2004, 33 : S36 - S36
[35] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
Smith, S. D.
Bolwell, B. J.
Rybicki, L. A.
Brown, S.
Dean, R.
Kalaycio, M.
Sobecks, R.
Andresen, S.
Hsi, E. D.
Pohlman, B.
Sweetenham, J. W.
BONE MARROW TRANSPLANTATION, 2007, 40 (03) : 239 - 243
[36] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
S D Smith
B J Bolwell
L A Rybicki
S Brown
R Dean
M Kalaycio
R Sobecks
S Andresen
E D Hsi
B Pohlman
J W Sweetenham
Bone Marrow Transplantation, 2007, 40 : 239 - 243
[37] HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR PRIMARY CNS LYMPHOMA - UPDATED RESULTS OF A PILOT AND PHASE II STUDY
Schorb, E.
Kasenda, B.
Fritsch, K.
Finke, J.
Illerhaus, G.
ANNALS OF ONCOLOGY, 2011, 22 : 92 - 92
[38] The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission:: the Spanish Lymphoma and Autologous Transplantation Group experience
Rodriguez, J.
Conde, E.
Gutierrez, A.
Arranz, R.
Leon, A.
Marin, J.
Bendandi, M.
Albo, C.
Caballero, M. D.
ANNALS OF ONCOLOGY, 2007, 18 (04) : 652 - 657
[39] Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Ruan, Jia
Zain, Jasmine
Palmer, Brett
Jovanovic, Borko
Mi, Xinlei
Swaroop, Alok
Winter, Jane N.
Gordon, Leo I.
Karmali, Reem
Moreira, Jonathan
Petrich, Adam M.
Pro, Barbara
BLOOD ADVANCES, 2023, 7 (19) : 5771 - 5779
[40] INTENSIFIED THERAPY PROGRAM FOLLOWED BY HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY
Russo, R. E.
Annibali, O.
Capria, S.
Di Rocco, A.
Finolezzi, E.
Avvisati, G.
Meloni, G.
Foa, R.
Martelli, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 649 - 649

← 1 2 3 4 5 →